• 1
    Barrett AJ. Mechanisms of the graft-versus-leukemia reaction. Stem Cells 1997; 15: 24858.
  • 2
    Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordignon C. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 171924.
  • 3
    Verzeletti S, Bonini C, Marktel S, Nobili N, Ciceri F, Traversari C, Bordignon C. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical followup and improved new vectors. Hum Gene Ther 1998; 9: 224351.
  • 4
    Takebayashi H, Oida H, Fujisawa K, Yamaguchi M, Hikida T, Fukumoto M, Narumiya S, Kakizuka A. Hormone-induced apoptosis by Fas-nuclear receptor fusion proteins: novel biological tools for controlling apoptosis in vivo. Cancer Res 1996; 56: 416470.
  • 5
    Kokubun M, Kume A, Urabe M, Mano H, Okubo M, Kasukawa R, Kakizuka A, Ozawa K. Apoptosis-mediated regulation of recombinant human granulocyte colony-stimulating factor production by genetically engineered fibroblasts. Gene Ther 1998; 5: 9239.
  • 6
    Mattioni T, Louvion J-F, Picard D. Regulation of protein activities by fusion to steroid binding domains. Methods Cell Biol 1994; 43: 33552.
  • 7
    Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 144956.
  • 8
    Gillis S, Smith KA. Long term culture of tumour-specific cytotoxic T cells. Nature 1977; 268: 1546.
  • 9
    Duke GM, Hoffman MA, Palmenberg AC. Sequence and structural elements that contribute to efficient encephalomyocarditis virus RNA translation. J Virol 1992; 66: 16029.
  • 10
    Kodaira H, Kume A, Ogasawara Y, Urabe M, Kitano K, Kakizuka A, Ozawa K. Fas and mutant estrogen receptor chimeric gene: a novel suicide vector for tamoxifen-inducible apoptosis. Jpn J Cancer Res 1998; 89: 7417.
  • 11
    Gorman C, Padmanabhan R, Howard BH. High efficiency DNA-mediated transformation of primate cells. Science 1983; 221: 5513.
  • 12
    Onishi M, Kinoshita S, Morikawa Y, Shibuya A, Phillips J, Lanier LL, Gorman DM, Nolan GP, Miyajima A, Kitamura T. Applications of retrovirus-mediated expression cloning. Exp Hematol 1996; 24: 3249.
  • 13
    Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991; 108: 193200.
  • 14
    Nakayama E, Shiku H, Takahashi T, Oettgen HF, Old LJ. Definition of a unique cell surface antigen of mouse leukemia RL male 1 by cell-mediated cytotoxicity. Proc Natl Acad Sci USA 1979; 76: 348690.
  • 15
    Grabstein K, Chen YU. Cell-mediated cytolytic responses. In: MishellBB, ShiigiSM, editors. Selected methods in cellular immunology. San Francisco : WH Freeman; 1980. p. 12437.
  • 16
    Watanabe-Fukunaga R, Brannan CI, Itoh N, Yonehara S, Copeland NG, Jenkins NA, Nagata S. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1992; 148: 12749.
  • 17
    Koike S, Sakai M, Muramatsu M. Molecular cloning and characterization of rat estrogen receptor cDNA. Nucleic Acids Res 1987; 15: 2499513.
  • 18
    Itoh N, Nagata S. A novel protein domain required for apoptosis. J Biol Chem 1993; 268: 109327.
  • 19
    Kumar V, Chambon P. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 1988; 55: 14556.
  • 20
    Braun MY, Lowin B, French L, Acha-Orbea H, Tschopp J. Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. JExp Med 1996; 183: 65761.
  • 21
    Baker MB, Riley RL, Podack ER, Levy RB. Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function. Proc Natl Acad Sci USA 1997; 94: 136671.
  • 22
    Schmaltz C, Alpdogan O, Horndasch KJ, Muriglan SJ, Kappel BJ, Teshima T, Ferrara JLM, Burakoff SJ, van den Brink MRM. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood 2001; 97: 288695.
  • 23
    Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 116978.
  • 24
    Ushiroyama T, Sugimoto O. Endocrine function of the peri- and postmeno-pausal ovary. Horm Res 1995; 44: 648.
  • 25
    Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 1995; 23: 168690.
  • 26
    Thomis DC, Marktel S, Bonini C, Traversari C, Gilman M, Bordignon C, Clackson T. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 2001; 97: 124957.
  • 27
    Fan L, Freeman KW, Khan T, Pham E, Spencer DM. Improved artificial death switches based on caspases and FADD. Hum Gene Ther 1999; 10: 227385.